Daniel Freitag Email & Phone Number

United Kingdom

Brentford, Middlesex, GB

Matrix leadership role with portfolio responsibility coordinating GSK’s industry leading in silico (Human Genetics & genomics) and in in vitro (Functional Genomics) capabilities. Accountable for developing and and delivering GSK’s portfolio of target discovery efforts (commit to target validation and commit to target milestones) in respiratory disease.

Brentford, Middlesex, GB

Built a framework for systematic use of human genetic data to inform translational project decisions (e.g. identification of target engagement biomarkers).

Leverkusen, North Rhine-Westphalia, DE

Responsible for a team of data scientists located in the research sites Wuppertal and Berlin. Mission of my team was to use multi-omics data (genomics, metabolomics, proteomics, etc) to make causal human biology accessible and quantifiable. Application focus was on cardiovascular, metabolic, renal, lung, acute care and women's health indications, from.

Leverkusen, North Rhine-Westphalia, DE

Responsible for establishing and developing the Biomedical Data Science function in Wuppertal (target state >10 FTE), within the newly established digital technologies department. Mission of my function is to enable data-driven decision making, with a focus on “multi–omics” data (e.g. genomics), in order to increase success rates of Pharma R&D projects.

Leverkusen, North Rhine-Westphalia, DE

I am heading the newly founded department of cardiovascular data sciences. My group is responsible for the identification, acquisition and analysis of complex, large-scale datasets for all areas of cardiovascular disease. We use state-of-the art statistical and computational methods to tackle such datasets to extract insights into disease biology and.

Leverkusen, North Rhine-Westphalia, DE

I am in charge of the development and implementation of human genomic approaches for the discovery and prioritisation of novel drug targets across key indications within the portfolio of Bayer Pharmaceuticals.

Cambridge, England, GB

I am in charge of establishing and developing the Cardiovascular Epidemiology Unit's capabilities in functional and translational genetics. This includes setting up a wet lab at the Wellcome Trust Sanger Institute, to enable functional genetic follow-up of genetic association signals using human induced pluripotent stem cells and model organisms. The aim.

Cambridge, England, GB

• Department: Public Health and Primary CarePhD title “Inflammatory pathways and the risk of Coronary Heart Disease”
• Full scholarship from the British Heart Foundation
• Collaborated with experts from academia and industry, conceived and designed research studies, analysed data, optimized molecular assays; Project-manager for collaboration with Pfizer, consultant for Pfizer and Novartis.
• Involved in teaching of graduate students: Held lectures on genetic epidemiology & translational medicine, supervised practicals

Würzburg, Bayern, DE

In charge of chemical synthesis and characterisation of coated SiO2-nanoparticles & identification of commercial applications (e.g. in medical diagnostics/imaging)

DE

Part-time employee for time of dissertation (Dipl. mol.-biomed.). Developed ex-vivo vessel perfusion system for targeted lentiviral gene transfer; coordinated collaboration with Department of Pharmacology on magnetic nanoparticle assisted cell positioning and lentiviral vector targeting

Philadelphia, PA, US

Department: Cardiovascular Medicine Division, University of Pennsylvania, USA Developed and validated molecular (RT-PCR) panel for characterization of cardiac derived progenitor cells from human hearts.

Leverkusen, North Rhine-Westphalia, DE

Department: Target-Discovery/Biomarkers II; Led project investigating the effect of tyrosine kinase inhibitors on cardiac hypertrophy

Master Of Philosophy (Mphil), Epidemiology

Diplom, Molecular Medicine